RegulationPriority Review (US), Fast Track (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (AU), Overseas New Drugs Urgently Needed in Clinical Settings (CN), Orphan Drug (JP)

Structure/Sequence

Molecular FormulaC10H10N2O

InChIKeyQELUYTUMUWHWMC-UHFFFAOYSA-N

CAS Registry89-25-8

Clinical Trials associated with Edaravone

NCT06757504

/ RecruitingPhase 2

A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-controlled Phase II Trial of TTYP01 Tablets in Adolescents and Children With Autism Spectrum Disorders

This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.

Start Date07 Jan 2025

Sponsor / Collaborator

Shanghai Auzone Biological Technology Co., Ltd.

ChiCTR2400094236

/ SuspendedPhase 3IIT

A clinical study on the treatment of cerebral small vessel disease-related cognitive dysfunction with edaravone sublingual tablets

Start Date30 Dec 2024

Sponsor / Collaborator-

IRCT20240224061102N1

/ SuspendedPhase 3IIT

Evaluation of the effect of edaravone on the patients with ischemic stroke

Start Date30 May 2024

Sponsor / Collaborator-

100 Clinical Results associated with Edaravone

100 Translational Medicine associated with Edaravone

100 Patents (Medical) associated with Edaravone

6,721

Literatures (Medical) associated with Edaravone

01 Jul 2025·BIOMATERIALS

Anti-neuroinflammatory agent rhein lysinate-based self-assembled injectable hydrogel loaded with ZL006 for promoting post-stroke functional recovery

Article

Author: Jiang, Nan ; Lin, Yuhui ; Song, Jiamei ; Li, Rui ; Wang, Jiayu ; Wang, Ruiqi ; Chen, Xi ; Zhang, Ying ; Gao, Yuhao ; Zeng, Jiaqi

The therapeutic agent-based self-assembled hydrogel is gaining interest for biomedical applications, because it overcomes the poor biodegradability and low therapeutic agent loading of conventional polymer gelator-based hydrogel. Here, we present rhein lysinate (RHL), a therapeutic agent that self-assembles to form a stable hydrogel through the π-π stacking and hydrogen bonding interactions, while also exerting anti-neuroinflammatory effect. As a small molecular hydrogelator, RHL has significantly improved water solubility and enhanced self-assembly and gelation capabilities compared to the natural anthraquinone rhein. The relaxed gel-forming conditions enhance the practical application potential of self-assembled hydrogel of RHL (RHL gel). The RHL gel can be loaded with the bioactive agents such as 5-Fluorouracil, temozolomide, edaravone, and ZL006, mainly based on efficient stacking between aromatic rings in the bioactive agents and anthraquinone rings in the hydrogel network structure. The pre-gelled RHL gel and ZL006-loaded RHL gel (ZL006-RHL gel) exhibit shear-thinning behavior, flowing like a liquid under high shear stress during injection. Once this shear stress is removal within the body, they rapidly recover to the initial solid-like state. When a single dose of ZL006-RHL gel is administrated to stroke cavity in the subacute phase of stroke, RHL gel matrix effectively reduces post-stroke neuroinflammation, creates a favorable environment for ZL006 to enhance neuroplasticity, and confers a sustained and stable action to ZL006, leading to a long-lasting improvement of motor performance. This study may provide a valuable strategy for therapeutic intervention to promote post-stroke functional recovery, for which there are no clinically available drugs.

04 Mar 2025·Journal of biomolecular structure & dynamics

Elemental evaluation, nutritional analysis, GC-MS analysis and ameliorative effects of Artocarpus communis J.R.Forst. & G.Forst. seeds’ phytoconstituents on metabolic syndrome via in silico approach

Article

Author: Awosola, Oyindamola Esther ; Ajayi-Odoko, Omolola Adenike ; Ayokunle, Damilare Iyinkristi ; Ojo, Oluwafemi Adeleke ; Sonibare, Mubo Adeola ; Babatunde, Dare Ezekiel ; Akintunde, Emmanuel Adewuni ; Ogunlakin, Akingbolabo Daniel ; Dahunsi, Olatunde Samuel ; Akinwumi, Idayat Adeola ; Gyebi, Gideon Ampoma ; Adebodun, Great Oluwamayokun ; Ambali, Owoola Azeezat ; Ayeni, Peluola Olujide

The nutritional as well as beneficial effects of the Artocarpus communis seed on metabolic syndrome complications have not been studied. In this research, the aim was to investigate the nutritional composition and beneficial effects of Artocarpus communis seeds' phytoconstituents on the p53 core, fat mass and obesity-associated (FTO) protein and cytochrome P450 CYP11A1 domains. The elements and phytochemicals in the seed were determined through atomic absorption spectroscopy assay and gas chromatography-mass spectrometry (GC-MS) analysis, respectively. Also, the compounds detected were docked to the p53 core, FTO protein and cytochrome P450 CYP11A1 domains protein. Artocarpus communis seed contains sodium (7.824 ± 0.0134 ppm), magnesium (10.187 ± 0.0239 ppm) and iron (1.924 ± 0.0017), while zinc and cadmium were undetected. Phenolics and flavonoids were the most abundant phytochemicals in the seed. Phytoconstituents, such as pentadecanoic acid, hexadecanoic acid and methyl ester, possessing different therapeutic effects were identified via GC-MS analysis. In A. communis seed, 3-methyl-4-nitro-5-(1-pyrazolyl) pyrazole and phenanthrene were able to bind more peculiarly and specifically to the p53 core, FTO protein and cytochrome P450 CYP11A1 domains. One of the important processes that were hypothesized for the recovery of metabolic syndrome in affected victims is shown by the molecular dynamics analysis, which shows that the binding of these chemicals to the targeted structure stabilized the proteins. Therefore, Artocarpus communis seeds could be a new strategy for the management of metabolic syndrome.Communicated by Ramaswamy H. Sarma.

01 Mar 2025·MOLECULAR NEUROBIOLOGY

Antioxidant Effect of Naringin Demonstrated Through a Bayes’ Theorem Driven Multidisciplinary Approach Reveals its Prophylactic Potential as a Dietary Supplement for Ischemic Stroke

Article

Author: Gogoi, Anaekshi ; Babu, Manju ; Datta, Arnab ; Shelley, Bhaskara P ; Seshadri, Meenakshi ; Ray, Animikh ; Rao, Rajas M ; Singh, Nikhil ; Jerom, Jenat Pazheparambil ; Babu, Anju

Naringin (NAR), a flavanone glycoside, occurs widely in citrus fruits, vegetables, and alcoholic beverages. Despite evidence of the neuroprotective effects of NAR on animal models of ischemic stroke, brain cell-type-specific data about the antioxidant efficacy of NAR and possible protein targets of such beneficial effects are limited. Here, we demonstrate the brain cell type-specific prophylactic role of NAR, an FDA-listed food additive, in an in vitro oxygen-glucose deprivation (OGD) model of cerebral ischemia using MTT and DCFDA assays. Using Bayes' theorem-based predictive model, we first ranked the top-10 protein targets (ALDH2, ACAT1, CTSB, FASN, LDHA, PTGS1, CTSD, LGALS1, TARDBP, and CDK1) from a curated list of 289 NAR-interacting proteins in neurons that might be mediating its antioxidant effect in the OGD model. When preincubated with NAR for 2 days, N2a and CTX-TNA2 cells could withstand up to 8 h of OGD without a noticeable decrease in cell viability. This cerebroprotective effect is partly mediated by reducing intracellular ROS production in the above two brain cell types. The antioxidant effect of NAR was comparable with the equimolar (50 µM) concentration of clinically used ROS-scavenger and neuroprotective edaravone. Molecular docking of NAR with the top-10 protein targets from Bayes' analysis showed the lowest binding energy for CDK1 (- 8.8 kcal/M). Molecular dynamics simulation analysis showed that NAR acts by inhibiting CDK1 by stably occupying its ATP-binding cavity. Considering diet has been listed as a risk factor for stroke, NAR may be explored as a component of functional food for stroke or related neurological disorders.

150

News (Medical) associated with Edaravone

17 Dec 2024

·www.prnewswire.com

Mitsubishi Tanabe Pharma America Announces Research Collaboration Between Mitsubishi Tanabe Pharma Corporation and Dewpoint Therapeutics to Advance Small Molecule Condensate Modulator for ALS

Collaboration aims to address underlying ALS pathology with innovative TDP-43 modulator technology JERSEY CITY, N.J., Dec. 17, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Mitsubishi Tanabe Pharma Corporation (MTPC), its parent company and a global leader in neurological disease therapeutics, has entered into a strategic research collaboration with Dewpoint Therapeutics, Inc. The collaboration focuses on developing a novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), furthering MTPC's commitment to advancing innovation in ALS and central nervous system (CNS) diseases. Under the terms of the agreement, MTPC will pay Dewpoint an upfront payment. Upon reaching certain pre-specified milestones, MTPC will have the exclusive option to license the program and assume responsibility for global clinical development and commercialization. "ALS remains one of the most challenging diseases to treat, with limited treatment options for patients," said Yasutoshi Kawakami, President, MTPA. "Through this collaboration with Dewpoint Therapeutics, we hope to advance innovative approaches to address this devastating disease by leveraging their expertise in condensate biology. Together, we are committed to making a meaningful difference for patients living with ALS." The TDP-43 small molecule condensate modulator is being developed to target key underlying biological mechanisms associated with ALS. TDP-43 is a protein known to play a critical role in ALS pathology, where its dysregulation contributes to neuronal cell death and dysfunction. This innovative approach seeks to address TDP-43's pathological aggregation, with the potential to advance understanding of ALS. This collaboration reflects MTPC's continued focus on central nervous system diseases, including ALS. With the development of RADICAVA® (edaravone) and RADICAVA ORS® (edaravone), MTPC remains a global leader in advancing ALS care and is committed to addressing the unmet needs of patients and families living with ALS. About Mitsubishi Tanabe Pharma America, Inc. Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit or follow us on X (formerly Twitter), Facebook and LinkedIn. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to . About Condensate Condensates are membraneless organelles that form dynamically throughout the cell via a process called phase separation. These subcellular compartments organize and concentrate biomolecules within cells to enable a diversity of key biochemical processes. The dysregulation of biomolecular condensates has been observed in many diseases, including cancer, diabetes, cardiovascular, and neurological disorders. Condensate modulators (cmods) potentially provide novel therapeutic options for complex diseases and historically undruggable targets. Media inquiries: [email protected] SOURCE Mitsubishi Tanabe Pharma America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/in

04 Dec 2024

·www.prnewswire.com

China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke

NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been approved for marketing by the National Medical Products Administration. This product is indicated for the improvement of neurological symptoms, daily activities, and functional impairment due to acute ischemic stroke. Continue Reading Packaging of Sanbexin® sublingual tablets Sanbexin® sublingual tablets is a dual-target brain cytoprotective agent composed of edaravone and dexborneol. These two active ingredients exert synergistic anti-oxidant and anti-inflammatory effects, which can significantly reduce brain cell damage caused by acute ischemic stroke. The sublingual tablets are designed for quick disintegration once in contact with saliva under the tongue. This facilitates the active ingredients' rapid absorption into the blood and brain through the sublingual venous plexus. Compared to conventional oral formulations, sublingual tablets bypass the first-pass hepatic metabolism, which is conducive to higher drug bioavailability and faster onset of action. Previously, Sanbexin® injection was approved for marketing in China in 2020. As the world's only innovative drug approved for stroke since 2015, it has helped over 3 million patients in the past 4 years. The phase III clinical trial led by Professor Fan Dongsheng of Peking University Third Hospital showed that the patients in the Sanbexin® sublingual tablets group after 14 consecutive days of drug administration, obtained a significantly higher proportion of functional independence outcome at 90 days post-treatment than those in the placebo group (64.4% vs. 54.7%,). The latest data was published in JAMA Neurology on February 19, 2024. Professor Fan Dongsheng, Principal Investigator of TASTE-SL and Professor at Peking University Third Hospital mentioned:"Sanbexin® sublingual tablets has shown significant effects and good safety in improving recovery of cerebral cells and independent living ability during the acute phase in patients with acute ischemic stroke. The more convenient administration allows for sequential therapy with Sanbexin® injection, facilitating stroke patients to receive a complete course of brain cytoprotection in and outside of the hospital during the acute phase of stroke." Professor Wang Yongjun, Director of Beijing Tiantan Hospital, Capital Medical University "The average length of hospital stay for stroke patients in China is about one week, while clinical studies suggest that brain cytoprotective drugs need to be used for 14 consecutive days. Sanbexin® sublingual tablets is easy to take, allowing patients to receive treatment at home. This can better reduce disability among patients and is also expected to lower medical costs." In August 2024, Sanbexin® sublingual tablets was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for AIS, making it the world's first innovative drug in the field of stroke treatment to have received such acknowledgment. Currently, a global multi-centered clinical trial of Sanbexin® sublingual tablets is under preparation. "The approval of Sanbexin® sublingual tablets in China is believed to significantly reduce the number of stroke-related disabilities in China." Professor Gregory W. Albers, Director of the Stroke Center and the Medical Center at Stanford University commented, " We are planning to conduct a large-scale Phase III clinical trial of Sanbexin® sublingual tablets in the United States, hoping to replicate the success of the trial in China and help reduce the global burden of stroke-related disabilities." Dr. Marc Fisher, former President of the World Stroke Organization and Professor at Harvard Medical School, commented on this new approval:"Sanbexin® has gradually gained popularity in China and is now available in a sublingual tablets formulation, with clinical data confirming its safety and efficacy. We are hoping to see trials of Sanbexin® sublingual tablets conducted outside China. If the trial results are positive and it receives approval in other countries, such as the U.S., it will have a huge impact globally on the treatment of acute ischemic stroke." The Sanbexin® sublingual tablets, with its convenient delivery method, will make stroke prevention and treatment more comprehensive and accessible. Its therapeutic area is expected to be expanded to pre-hospital emergency treatment for the acute phase of stroke, as well as to the treatment for the sub-acute and chronic phases of cerebrovascular diseases, to further promote the recovery of neurological functions and to improve the functional prognosis of stroke patients. SOURCE Simcere Pharmaceutical Group Limited WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Drug ApprovalBreakthrough TherapyClinical Result

04 Dec 2024

·www.biopharmadive.com

Dewpoint, Mitsubishi partner on ALS drug in deal worth up to $480M

Dewpoint Therapeutics, a young biotechnology company, could receive nearly half a billion dollars if all goes to plan in a new partnership focused on its experimental medicine for ALS.Through a deal announced Wednesday, Dewpoint has given Mitsubishi Tanabe Pharma the exclusive right to license the medicine once it hits certain near-term research and development goals. Should Mitsubishi Tanabe choose to license the program, the Japan-based company would then be responsible for its clinical development and commercialization.In exchange, Dewpoint has received an undisclosed upfront sum of money and could take home more through milestone and tiered royalty payments. The total value of the deal could reach as high as $480 million.Mitsubishi Tanabe a distant corporate cousin of the car manufacturer already sells Radicava, one of the few drugs approved in the U.S. to treat amyotrophic lateral sclerosis. Radicava is available as an infusion or, since 2022, a mixture taken orally. Doctors have said the drug offers only modest effects and its administration, at least with the infused version, can be so cumbersome that patients often dont find it worthwhile.With limited treatment options, people with ALS currently live an average of two to five years after they are diagnosed. Roughly 90% of cases are classified as sporadic, meaning experts dont know the root cause.ALS remains a critical area of unmet medical needs and [Mitsubishi Tanabe] is committed to addressing it, said Masao Nawano, head of the companys research division, in a statement. Together with Dewpoint, we have the potential to deliver meaningful innovations to patients and families affected by this devastating condition.Launched in 2019, Dewpoint believes that mysterious clusters of molecules may be a path to new drugs for cancer, heart conditions and nerve-destroying disorders like ALS. Studies have suggested these clusters, known as biomolecular condensates, are important in cell regulation and may causes diseases if they malfunction.The idea has intrigued venture capitalists, giving rise to a few startups that debuted shortly after Dewpoint. Nereid Therapeutics launched in the middle of November 2020 with $50 million in funding from Apple Tree Partners. Two weeks later, Transition Bio unveiled itself and announced the closing of a seed funding round led by Lifeforce Capital.Faze Medicines also emerged in late 2020, backed by powerful investment firms like Third Rock Ventures and Alexandria Venture Investments as well as large pharmaceutical companies like Novartis, AbbVie and Eli Lilly. Yet less than two years later, Faze abruptly shut down. The companys science did not progress sufficiently to meet our bar for further investment, a Third Rock spokesperson said at the time.Dewpoint, meanwhile, has continued to draw in money since its launch. The company inked collaborations with Bayer, Merck & Co., Pfizer and Novo Nordisk that collectively could be worth well over $1 billion.Some of that money hasn't materialized, though. The company reportedly lost its alliances with Merck and Pfizer, and laid off staff earlier this year.Ameet Nathwani, Dewpoints CEO and a former Sanofi executive, said in a statement that Mitsubishi Tanabe is the ideal partner for the ALS program, given the companys knowledge of the disease and its global clinical capability and expansive patient network.Dewpoints drug is meant to treat ALS by breaking up abnormal accumulations of a protein called TDP-43. This protein is essential for processing RNA, and some scientists believe that when it stops functioning correctly, or when there isnt enough of it in the core of nerve cells, diseases like ALS can develop. '

License out/in

100 Deals associated with Edaravone

External Link

KEGG	Wiki	ATC	Drug Bank
D01552	Edaravone	N07XX14	DB12243

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis	JP	Mitsubishi Tanabe Pharma Corp.	26 Jun 2015
Brain Infarction	JP	Mitsubishi Tanabe Pharma Corp.	26 Jun 2015
Acute Ischemic Stroke	CN	Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd.	31 Dec 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis 2, Juvenile	Phase 3	JP	Mitsubishi Tanabe Pharma Corp.	01 Dec 2011
Alzheimer Disease	Phase 3	NL	Treeway BV	-
Autism Spectrum Disorder	Phase 2	CN	Shanghai Auzone Biological Technology Co., Ltd.	24 Dec 2024
Autistic Disorder	Phase 2	CN	Shanghai Auzone Biological Technology Co., Ltd.	-
liver function failure	Phase 1	JP	Mitsubishi Tanabe Pharma Corp.	16 Nov 2016
Liver Injury	Phase 1	JP	Mitsubishi Tanabe Pharma Corp.	16 Nov 2016
Renal Insufficiency	Phase 1	JP	Mitsubishi Tanabe Pharma Corp.	27 Oct 2016
Retinal Dystrophies	Preclinical	-	-	01 May 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05568615 (CTgov)	Phase 3	Amyotrophic Lateral Sclerosis	15	MT-1186	hxomhmzxeo(zljrccifnx) = grsrhjadtq zhajajyxyh (bxhflabdyx, ptbdxaypwh - trcwcucatw) View more	-	03 Feb 2025
NCT03346538 (CTgov)	Phase 2	Acute Ischemic Stroke	17	Approved dosing regimen placebo+Continuous infusion high-dose MCI-186 (Continuous Infusion High-dose Group (Group H))	sdorjrapmj(bqgswkasyk) = uoddajvxfh qpkndyzagt (apwxcmaprp, ymqjlwzvry - tqgkmhdtmi) View more	-	09 Jan 2025
				Approved dosing regimen placebo+Continuous infusion low-dose MCI-186 (Continuous Infusion Low-dose Group (Group L))	sdorjrapmj(bqgswkasyk) = nmrpfdqxym qpkndyzagt (apwxcmaprp, xywbsbddaf - vrxfrpfonz) View more
NCT04577404 (MT-1186-A03, CTgov)	Phase 3	Amyotrophic Lateral Sclerosis	124	MT-1186	cnjvpmsufc(zibvlpsuey) = ptxjcvqulp zygfpdyyfp (fsuuhqauxk, bhadyglshj - kfqvdfatxf) View more	-	28 Aug 2024
NCT04577404 (MT-1186-A03, Biospace) Manual	Phase 3	Amyotrophic Lateral Sclerosis	-	RADICAVA ORS	ewbpdfsnuw(qyvkszwamp) = fall, muscular weakness, dyspnea, constipation, and dysphagia. mqjumbslvv (xbkcqcuike )	Positive	17 Jun 2024
AAN2024	Not Applicable	Amyotrophic Lateral Sclerosis	231	IV edaravone to oral edaravone	wkmsldpfgq(wwbgqoejtf) = hpwecannos fqjjxsoaqe (rwqilvaxlv ) View more	Positive	09 Apr 2024
				Oral edaravone-naïve	wkmsldpfgq(wwbgqoejtf) = uqnnbirghw fqjjxsoaqe (rwqilvaxlv ) View more
AAN2024	Not Applicable	Amyotrophic Lateral Sclerosis	-	Edaravone-naive patients	rtibatrdzs(dvwmpdfrgs) = rbjzwmqdqf bqiityypcp (tmtaypkgrp )	-	09 Apr 2024
				Edaravone-experienced patients	rtibatrdzs(dvwmpdfrgs) = dlvysuhpgt bqiityypcp (tmtaypkgrp )
MDA2024	Not Applicable	Amyotrophic Lateral Sclerosis	-	Edaravone-naïve patients	mdmxqjnnow(rblupposyj) = fylkpsqrvj ckepokyssq (nhubalizwd )	-	03 Mar 2024
				Edaravone-experienced patients	mdmxqjnnow(rblupposyj) = ktgqmawbet ckepokyssq (nhubalizwd )
NCT04254913 (CTgov)	Phase 1	Amyotrophic Lateral Sclerosis	6	MT-1186	ooevctrkzb(tztoxqyacw) = gfauipjznj owdwuoeugd (blmsmieaoy, mincdtsojw - cvyvwiyhao) View more	-	24 Jan 2024
NCT04176224 (CTgov)	Phase 1	Amyotrophic Lateral Sclerosis	9	MT-1186	iqvktbllei(fyslwjtztr) = oidiszjcye mrnwdlyzrc (lqjiqcpeis, jtdqrrsbju - cjvuwphgoc) View more	-	24 Jan 2024
NCT04493281 (CTgov)	Phase 1	-	42	Edaravone (Edaravone Oral Suspension)	awyuocdcmm(ksentsuzvw) = joxchjfehk svnbuodswk (sgkvzmrtqv, ecgcmvphxl - mzbvglsmxn) View more	-	18 Jan 2024
				Edaravone IV+Edaravone (Edaravone IV Formulation)	awyuocdcmm(ksentsuzvw) = fubsbwrryt svnbuodswk (sgkvzmrtqv, ebaviybjsz - evuisrcrqr) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Edaravone

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation